Advertisement

Management of Primary CNS Lymphoma in Elderly Patients

  • Andreas F. HottingerEmail author
  • Bianca Moura
  • Francesco Grandoni
  • Rita De Micheli
Chapter

Abstract

Primary central nervous system lymphoma (PCNSL) describes a malignant extranodal non-Hodgkin’s lymphoma (NHL) whose sole site of involvement is, by definition, the central nervous system. Most PCNSL cases present in the supratentorial space, most commonly in the frontal or temporo-parietal lobes, followed by the basal ganglia. Rarely, the disease may present in the cerebellum, brainstem or even the spinal cord. The disease may include the eyes and leptomeninges. PCNSL must be differentiated from systemic NHL with metastasis to the central nervous system.

Keywords

Primary Central Nervous System Lymphoma Immunocompetent Patient Anaplastic Large Cell Lymphoma Intraocular Lymphoma Primary Central Nervous System Lymphoma Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Hoang-Xuan K, Bessell E, Bromberg J et al (2015) Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncol 16:e322–e332CrossRefPubMedGoogle Scholar
  2. 2.
    Schabet M (1999) Epidemiology of primary CNS lymphoma. J Neurooncol 43:199–201CrossRefPubMedGoogle Scholar
  3. 3.
    Kadan-Lottick NS, Skluzacek MC, Gurney JG (2002) Decreasing incidence rates of primary central nervous system lymphoma. Cancer 95:193–202CrossRefPubMedGoogle Scholar
  4. 4.
    Cote TR, Manns A, Hardy CR et al (1996) Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. AIDS/Cancer Study Group. J Natl Cancer Inst 88:675–679CrossRefPubMedGoogle Scholar
  5. 5.
    Fine HA, Mayer RJ (1993) Primary central nervous system lymphoma. Ann Intern Med 119:1093–1104CrossRefPubMedGoogle Scholar
  6. 6.
    Corry J, Smith JG, Wirth A et al (1998) Primary central nervous system lymphoma: age and performance status are more important than treatment modality. Int J Radiat Oncol Biol Phys 41:615–620CrossRefPubMedGoogle Scholar
  7. 7.
    Ferreri AJ, Blay JY, Reni M et al (2003) Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 21:266–272CrossRefPubMedGoogle Scholar
  8. 8.
    Abrey LE, Ben-Porat L, Panageas KS et al (2006) Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 24:5711–5715CrossRefPubMedGoogle Scholar
  9. 9.
    Herrlinger U, Schabet M, Bitzer M et al (1999) Primary central nervous system lymphoma: from clinical presentation to diagnosis. J Neurooncol 43:219–226CrossRefPubMedGoogle Scholar
  10. 10.
    Besson C, Goubar A, Gabarre J et al (2001) Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 98:2339–2344CrossRefPubMedGoogle Scholar
  11. 11.
    Bataille B, Delwail V, Menet E et al (2000) Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg 92:261–266CrossRefPubMedGoogle Scholar
  12. 12.
    Camilleri-Broet S, Martin A, Moreau A et al (1998) Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Groupe Ouest Est d’etude des Leucenies et Autres Maladies du Sang (GOELAMS). Am J Clin Pathol 110:607–612CrossRefPubMedGoogle Scholar
  13. 13.
    Lachance DH, O’Neill BP, Macdonald DR et al (1991) Primary leptomeningeal lymphoma: report of 9 cases, diagnosis with immunocytochemical analysis, and review of the literature. Neurology 41:95–100CrossRefPubMedGoogle Scholar
  14. 14.
    Balmaceda C, Gaynor JJ, Sun M et al (1995) Leptomeningeal tumor in primary central nervous system lymphoma: recognition, significance, and implications. Ann Neurol 38:202–209CrossRefPubMedGoogle Scholar
  15. 15.
    Grimm SA, McCannel CA, Omuro AM et al (2008) Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report. Neurology 71:1355–1360CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Kawasaki K, Wakabayashi K, Koizumi T et al (2002) Spinal cord involvement of primary central nervous system lymphomas: histopathological examination of 14 autopsy cases. Neuropathology 22:13–18CrossRefPubMedGoogle Scholar
  17. 17.
    Braus DF, Schwechheimer K, Muller-Hermelink HK et al (1992) Primary cerebral malignant non-Hodgkin’s lymphomas: a retrospective clinical study. J Neurol 239:117–124CrossRefPubMedGoogle Scholar
  18. 18.
    Shaw A, Iyer V, Rooney N et al (2014) Diagnosis of primary cerebral lymphomas: possible value of PCR testing in equivocal cases requiring rebiopsy. Br J Neurosurg 28:214–219CrossRefPubMedGoogle Scholar
  19. 19.
    Mansour A, Qandeel M, Abdel-Razeq H, Abu Ali HA (2014) MR imaging features of intracranial primary CNS lymphoma in immune competent patients. Cancer Imaging 14:22PubMedPubMedCentralGoogle Scholar
  20. 20.
    Haldorsen IS, Espeland A, Larsson EM (2011) Central nervous system lymphoma: characteristic findings on traditional and advanced imaging. AJNR Am J Neuroradiol 32:984–992CrossRefPubMedGoogle Scholar
  21. 21.
    DeAngelis LM (1999) Primary central nervous system lymphoma. Curr Opin Neurol 12:687–691CrossRefPubMedGoogle Scholar
  22. 22.
    Nasir S, DeAngelis LM (2000) Update on the management of primary CNS lymphoma. Oncology (Williston Park) 14:228–234; discussion 237–242, 244Google Scholar
  23. 23.
    Pasricha S, Gupta A, Gawande J et al (2011) Primary central nervous system lymphoma: a study of clinicopathological features and trend in western India. Indian J Cancer 48:199–203CrossRefPubMedGoogle Scholar
  24. 24.
    Ivers LC, Kim AY, Sax PE (2004) Predictive value of polymerase chain reaction of cerebrospinal fluid for detection of Epstein-Barr virus to establish the diagnosis of HIV-related primary central nervous system lymphoma. Clin Infect Dis 38:1629–1632CrossRefPubMedGoogle Scholar
  25. 25.
    Gleissner B, Siehl J, Korfel A et al (2002) CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes. Neurology 58:390–396CrossRefPubMedGoogle Scholar
  26. 26.
    Galoin S, Daste G, Apoil PA et al (1997) Polymerase chain reaction on cerebrospinal fluid cells in the detection of leptomeningeal involvement by B-cell lymphoma and leukaemia: a novel strategy and its implications. Br J Haematol 99:122–130CrossRefPubMedGoogle Scholar
  27. 27.
    Yanagisawa K, Tanuma J, Hagiwara S et al (2013) Epstein-Barr viral load in cerebrospinal fluid as a diagnostic marker of central nervous system involvement of AIDS-related lymphoma. Intern Med 52:955–959CrossRefPubMedGoogle Scholar
  28. 28.
    Pell MF, Thomas DG, Whittle IR (1991) Stereotactic biopsy of cerebral lesions in patients with AIDS. Br J Neurosurg 5:585–589CrossRefPubMedGoogle Scholar
  29. 29.
    Luzzati R, Ferrari S, Nicolato A et al (1996) Stereotactic brain biopsy in human immunodeficiency virus-infected patients. Arch Intern Med 156:565–568CrossRefPubMedGoogle Scholar
  30. 30.
    Cinque P, Brytting M, Vago L et al (1993) Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system. Lancet 342:398–401CrossRefPubMedGoogle Scholar
  31. 31.
    De Luca A, Antinori A, Cingolani A et al (1995) Evaluation of cerebrospinal fluid EBV-DNA and IL-10 as markers for in vivo diagnosis of AIDS-related primary central nervous system lymphoma. Br J Haematol 90:844–849CrossRefPubMedGoogle Scholar
  32. 32.
    Arribas JR, Clifford DB, Fichtenbaum CJ et al (1995) Detection of Epstein-Barr virus DNA in cerebrospinal fluid for diagnosis of AIDS-related central nervous system lymphoma. J Clin Microbiol 33:1580–1583PubMedPubMedCentralGoogle Scholar
  33. 33.
    Henry JM, Heffner RRJ, Dillard SH et al (1974) Primary malignant lymphomas of the central nervous system. Cancer 34:1293–1302CrossRefPubMedGoogle Scholar
  34. 34.
    Bellinzona M, Roser F, Ostertag H et al (2005) Surgical removal of primary central nervous system lymphomas (PCNSL) presenting as space occupying lesions: a series of 33 cases. Eur J Surg Oncol 31:100–105CrossRefPubMedGoogle Scholar
  35. 35.
    Lai R, Rosenblum MK, DeAngelis LM (2002) Primary CNS lymphoma: a whole-brain disease? Neurology 59:1557–1562CrossRefPubMedGoogle Scholar
  36. 36.
    Weller M, Martus P, Roth P et al (2012) Surgery for primary CNS lymphoma? Challenging a paradigm. Neuro Oncol 14:1481–1484CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Roth P, Happold C, Weller M (2015) Corticosteroid use in neuro-oncology: an update. Neurooncol Pract 2:6–12PubMedGoogle Scholar
  38. 38.
    Weller M (1999) Glucocorticoid treatment of primary CNS lymphoma. J Neurooncol 43:237–239CrossRefPubMedGoogle Scholar
  39. 39.
    Singh A, Strobos RJ, Singh BM et al (1982) Steroid-induced remissions in CNS lymphoma. Neurology 32:1267–1271CrossRefPubMedGoogle Scholar
  40. 40.
    Todd FD, Miller CA, Yates AJ, Mervis LJ (1986) Steroid-induced remission in primary malignant lymphoma of the central nervous system. Surg Neurol 26:79–84CrossRefPubMedGoogle Scholar
  41. 41.
    Nelson DF, Martz KL, Bonner H et al (1992) Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 23:9–17CrossRefPubMedGoogle Scholar
  42. 42.
    Ling SM, Roach M, Larson DA, Wara WM (1994) Radiotherapy of primary central nervous system lymphoma in patients with and without human immunodeficiency virus. Ten years of treatment experience at the University of California San Francisco. Cancer 73:2570–2582CrossRefPubMedGoogle Scholar
  43. 43.
    DeAngelis LM, Yahalom J, Thaler HT, Kher U (1992) Combined modality therapy for primary CNS lymphoma. J Clin Oncol 10:635–643CrossRefPubMedGoogle Scholar
  44. 44.
    Blay JY, Bouhour D, Carrie C et al (1995) The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin’s lymphoma of patients with no known cause of immunosuppression. Blood 86:2922–2929PubMedGoogle Scholar
  45. 45.
    O’Brien P, Roos D, Pratt G et al (2000) Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 18:519–526CrossRefPubMedGoogle Scholar
  46. 46.
    Omuro AM, DeAngelis LM, Yahalom J, Abrey LE (2005) Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up. Neurology 64:69–74CrossRefPubMedGoogle Scholar
  47. 47.
    Bessell EM, Graus F, Lopez-Guillermo A et al (2004) Primary non-Hodgkin’s lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors. Int J Radiat Oncol Biol Phys 59:501–508CrossRefPubMedGoogle Scholar
  48. 48.
    Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H et al (2003) High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 21:4483–4488CrossRefPubMedGoogle Scholar
  49. 49.
    Gavrilovic IT, Hormigo A, Yahalom J et al (2006) Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 24:4570–4574CrossRefPubMedGoogle Scholar
  50. 50.
    Ghesquieres H, Ferlay C, Sebban C et al (2010) Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Ann Oncol 21:842–850CrossRefPubMedGoogle Scholar
  51. 51.
    Thiel E, Korfel A, Martus P et al (2010) High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 11:1036–1047CrossRefPubMedGoogle Scholar
  52. 52.
    Lachance DH, Brizel DM, Gockerman JP et al (1994) Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: short-duration response and multifocal intracerebral recurrence preceding radiotherapy. Neurology 44:1721–1727CrossRefPubMedGoogle Scholar
  53. 53.
    Schultz C, Scott C, Sherman W et al (1996) Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06. J Clin Oncol 14:556–564CrossRefPubMedGoogle Scholar
  54. 54.
    Shibamoto Y, Tsutsui K, Dodo Y et al (1990) Improved survival rate in primary intracranial lymphoma treated by high-dose radiation and systemic vincristine-doxorubicin-cyclophosphamide-prednisolone chemotherapy. Cancer 65:1907–1912CrossRefPubMedGoogle Scholar
  55. 55.
    Stewart DJ, Russell N, Atack EA et al (1983) Cyclophosphamide, doxorubicin, vincristine, and dexamethasone in primary lymphoma of the brain: a case report. Cancer Treat Rep 67:287–291PubMedGoogle Scholar
  56. 56.
    Hiraga S, Arita N, Ohnishi T et al (1999) Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas. J Neurosurg 91:221–230CrossRefPubMedGoogle Scholar
  57. 57.
    Glass J, Gruber ML, Cher L, Hochberg FH (1994) Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 81:188–195CrossRefPubMedGoogle Scholar
  58. 58.
    Morris PG, Correa DD, Yahalom J et al (2013) Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol 31:3971–3979CrossRefPubMedGoogle Scholar
  59. 59.
    Ferreri AJ, Reni M, Foppoli M et al (2009) High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 374:1512–1520CrossRefPubMedGoogle Scholar
  60. 60.
    Pels H, Schmidt-Wolf IG, Glasmacher A et al (2003) Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 21:4489–4495CrossRefPubMedGoogle Scholar
  61. 61.
    Hoang-Xuan K, Taillandier L, Chinot O et al (2003) Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 21:2726–2731CrossRefPubMedGoogle Scholar
  62. 62.
    Fritsch K, Kasenda B, Hader C et al (2011) Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly. Ann Oncol 22:2080–2085CrossRefPubMedGoogle Scholar
  63. 63.
    Ney DE, Reiner AS, Panageas KS et al (2010) Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center experience. Cancer 116:4605–4612CrossRefPubMedGoogle Scholar
  64. 64.
    Omuro AM, Taillandier L, Chinot O et al (2007) Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol 85:207–211CrossRefPubMedGoogle Scholar
  65. 65.
    Roth P, Martus P, Kiewe P et al (2012) Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial. Neurology 79:890–896CrossRefPubMedGoogle Scholar
  66. 66.
    Illerhaus G, Muller F, Feuerhake F et al (2008) High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica 93(1):147–148CrossRefPubMedGoogle Scholar
  67. 67.
    Schuurmans M, Bromberg JE, Doorduijn J et al (2010) Primary central nervous system lymphoma in the elderly: a multicentre retrospective analysis. Br J Haematol 151:179–184CrossRefPubMedGoogle Scholar
  68. 68.
    Taoka K, Okoshi Y, Sakamoto N et al (2010) A nonradiation-containing, intermediate-dose methotrexate regimen for elderly patients with primary central nervous system lymphoma. Int J Hematol 92:617–623CrossRefPubMedGoogle Scholar
  69. 69.
    Zhu JJ, Gerstner ER, Engler DA et al (2009) High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro Oncol 11:211–215CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Kurzwelly D, Glas M, Roth P et al (2010) Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. J Neurooncol 97:389–392CrossRefPubMedGoogle Scholar
  71. 71.
    Welch MR, Omuro A, Deangelis LM (2012) Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center. Neuro Oncol 14:1304–1311CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Illerhaus G, Marks R, Muller F et al (2009) High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Ann Oncol 20:319–325CrossRefPubMedGoogle Scholar
  73. 73.
    Jahnke K, Korfel A, Martus P et al (2005) High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol 16:445–449CrossRefPubMedGoogle Scholar
  74. 74.
    Bessell EM, Dickinson P, Dickinson S, Salmon J (2011) Increasing age at diagnosis and worsening renal function in patients with primary central nervous system lymphoma. J Neurooncol 104:191–193CrossRefPubMedGoogle Scholar
  75. 75.
    Omuro A, Chinot O, Taillandier L et al (2015) Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. Lancet Haematol 2:e251–e259CrossRefPubMedGoogle Scholar
  76. 76.
    Correa DD, Shi W, Abrey LE et al (2012) Cognitive functions in primary CNS lymphoma after single or combined modality regimens. Neuro Oncol 14:101–108CrossRefPubMedGoogle Scholar
  77. 77.
    Ferreri AJ, Blay JY, Reni M et al (2002) Relevance of intraocular involvement in the management of primary central nervous system lymphomas. Ann Oncol 13:531–538CrossRefPubMedGoogle Scholar
  78. 78.
    Ponzoni M, Terreni MR, Ciceri F et al (2002) Primary brain CD30+ ALK1+ anaplastic large cell lymphoma (‘ALKoma’): the first case with a combination of ‘not common’ variants. Ann Oncol 13:1827–1832CrossRefPubMedGoogle Scholar
  79. 79.
    Shenkier TN, Blay JY, O’Neill BP et al (2005) Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol 23:2233–2239CrossRefPubMedGoogle Scholar
  80. 80.
    McCue MP, Sandrock AW, Lee JM et al (1993) Primary T-cell lymphoma of the brainstem. Neurology 43:377–381CrossRefPubMedGoogle Scholar
  81. 81.
    Villegas E, Villa S, Lopez-Guillermo A et al (1997) Primary central nervous system lymphoma of T-cell origin: description of two cases and review of the literature. J Neurooncol 34:157–161CrossRefPubMedGoogle Scholar
  82. 82.
    Ferreri AJ, Reni M, Pasini F et al (2002) A multicenter study of treatment of primary CNS lymphoma. Neurology 58:1513–1520CrossRefPubMedGoogle Scholar
  83. 83.
    Baehring JM, Damek D, Martin EC et al (2003) Neurolymphomatosis. Neuro Oncol 5:104–115CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  • Andreas F. Hottinger
    • 1
    Email author
  • Bianca Moura
    • 2
  • Francesco Grandoni
    • 2
  • Rita De Micheli
    • 2
  1. 1.Departments of Clinical Neurosciences & OncologyLausanne University HospitalLausanne CHUVSwitzerland
  2. 2.Department of OncologyLausanne University HospitalLausanne CHUVSwitzerland

Personalised recommendations